Keytruda biosimilars are coming — but they face an uphill battle

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 02 Nov, 14:34 UTC

A patent cliff is fast approaching for Merck’s flagship blockbuster, but the deck might be stacked against its biosimilars gaining widespread traction.

science

Sources

• T2Keytruda biosimilars are coming — but they face an uphill battleBioPharma Dive / Healthcare Dive / MedTech Dive02 Nov, 14:34